Navigation Links
Stem Cell Biotherapy Sues Casey Nabavi, Co-Founder and Former President, for Conduct Resulting in Claims by SCB Patients Against Nabavi, Embezzling Money and Converting Other Assets Belonging to SCB and for Wrongfully Establishing Cellulogix Biosciences t
Date:4/1/2009

LOS ANGELES and TAMPA, Fla., April 1 /PRNewswire/ -- Stem Cell Biotherapy ("SCB") announced that it filed a lawsuit today in Los Angeles County Superior Court against the Company's Co-Founder and former President Casey Nabavi of Calabasas, California, for among other things conduct by Nabavi giving rise to patient claims against Nabavi that he had misrepresented himself as a medical doctor, practiced medicine without a license, supervised the injection of stem cells which caused some patients to become ill and personally advised patients how to manage these side effects. Nabavi/Cellulogix have offices/clinics in Los Angeles, Tampa, Montreal, Zona Rio (Mexico) and Istanbul.

The SCB lawsuit also seeks to recover SCB funds in excess of $1.65 million that Navabi paid himself before leaving SCB, to recover assets including intellectual property belonging to SCB which Navabi took and used to start-up the new Cellulogix business, to prevent Nabavi from continuing to compete with SCB in contravention of the parties' non-competition agreement and for SCB to recover ownership, the business and profits of Cellulogix as belonging to SCB not to Navabi as a result of Nabavi's wrongful conduct and activities. A copy of the SCB lawsuit against Nabavi and Cellulogix can be viewed at the Company's web site www.stemcellbiotherapy.com at "Recent News".

SCB is in the business of assisting persons who desire to try stem cell therapy treatment for serious medical problems which have not responded to traditional medical treatments. SCB uses medical clinics and specialized doctors in locations around the world where stem cell therapy is authorized to treat medical conditions such as spinal cord injury, ALS, Parkinsonism, Alzheimer's, multiple sclerosis, autism, cerebral palsy, brain damage, heart disease, COPD, kidney diseases, eye diseases, diabetes, transverse myelitis, etc. SCB also offers age rejuvenation programs for persons seeking to reverse the effects of aging.

The U.S. FDA recently announced that it was approving Geron Corporation to engage in a clinical trial with embryonic stem cells to treat spinal cord injuries; and the Obama Administration recently reversed the Bush Administration's prohibition against federal funding for embryonic stem cell research.

    For Further Information, Contact
    Burton Feinerman, M.D. at SCB
    1-888-620-0411
   http://www.stemcellbiotherapy.com/


'/>"/>
SOURCE Stem Cell Biotherapy
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. A potential molecular target for biotherapy esophageal squamous cell carcinomas
2. IntegriChain Enlists Ed Casey and Associates to Drive Counterfeit and Diversion Monitoring Service
3. The National Association for Home Care & Hospice (NAHC) Joins Sens. Susan Collins and Bob Casey and Reps. Jim McGovern and Walter Jones in Urging Access to Home Health Care
4. Casey Family Programs Hires Ken Patterson as Managing Director of Child and Family Services
5. Casey Family Programs Appoints Dr. America Bracho as New Board Member
6. Casey Family Programs Appoints New Board Members
7. Casey Family Programs Names Alabamas Walley Managing Director for Strategic Consulting
8. Columbus Medicare Diabetes Screening Project Cited as Model for State by Lt. Governor Casey Cagle
9. GeoVax Co-Founder Dr. Harriet Robinson Named 2007 AAAS Fellow
10. Intel Co-Founder Andrew S. Grove Dedicates Portion of His Estate, Up to $40 Million, to Michael J. Fox Foundation
11. Statement by Steve Case, Co-Founder, AOL and Chairman of Accelerate Brain Cancer Cure (www.ABC2.org) on News of Senator Ted Kennedys Brain Cancer Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... 23, 2017 , ... Arizona Spine & Joint Hospital ... designation of High Performing Hospitals by U.S. News & World Report for knee replacement ... significantly better than the national average in a given procedure or condition.  , ...
(Date:8/23/2017)... ... August 23, 2017 , ... Virsys12, ... strategic growth plans, announcing the hiring of Kevin Keelan as a Senior Account ... seasoned sales manager, Keelan will be working with Virsys12 senior leadership to extend ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... unique masks and serums that perfectly fuse the beauty of naturally derived ingredients ... 2017 Indie Beauty Expo on August 23rd & 24th in New York City. ...
(Date:8/22/2017)... ... August 22, 2017 , ... Pivot Point Consulting, ... Zack Tisch as the firm’s new Consulting Services Executive. Mr. Tisch will oversee ... accounts, from assisting clients with initial vendor selection and pre-implementation planning through go-live ...
(Date:8/22/2017)... ... ... is new to the Texas market, but is proudly managed by widely recognized All Star ... in Grand Prairie, TX, located in the center of the DFW Metroplex, the fourth largest ... the past 40 years with 32 convenient locations in Texas, Nevada and California resulting in ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... and PETACH TIKVAH, Israel , Aug. ... a leading developer of adult stem cell technologies for ... ending June 30, 2017. ... for our pivotal Phase 3 trial to investigate NurOwn ... President and Chief Executive Officer of BrainStorm. "We have ...
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
(Date:8/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2017. The cash dividend ... October 27, 2017 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
Breaking Medicine Technology: